Abstract
In the post genome era it will soon be possible to associate a specific tumor type with a specific gene expression profile and to define each molecular lesion characteristic of any given cancer. It is intuitive that a successful therapeutic strategy for cancer should aim at blocking the aberrant biochemical activity triggered by the oncogene or the lack of tumor suppressor gene activity that ultimately leads to full-blown neoplastic transformation. However, an attractive alternative approach entails the blockade of the transcriptional consequences of such oncogenic activities irrespective of their original biochemical nature, thus antagonizing the key transcriptional events underlying cancer pathogenesis in any specific neoplastic cellular population. This approach is now rendered possible by major advances along several lines of investigation: (i) the possibility of analysing gene expression through high throughput methods; (ii) a more detailed knowledge of the regulatory regions and of the transcription factors that control gene expression also facilitated in the future by a comprehensive whole genome comparative analysis of these regulatory sequences; (iii) the ability of modulating gene expression at the single gene level through various approaches both pharmacological and biochemical; (iv) the opportunity of directly antagonizing the aberrant activities of oncogenic transcription factors through a detailed knowledge of their abnormal transcriptional function; (v) the possibility of validating, in vivo, in animal models the relevance for neoplastic transformation of specific transcriptional events as well as of testing the efficacy of ‘transcription therapy’ in faithful animal models of human cancer. Here, we will review the facts, the existing applications and the hypothesis underlying such therapeutic modality for cancer therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aman P . 1999 Semin. Cancer Biol. 9: 303–318
Arnould C, Philippe C, Bourdon V, Gregoire MJ, Berger R, Jonveaux P . 1999 Hum. Mol. Genet. 8: 1741–1749
Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP . 1998 Adv. Cancer Res. 72: 141–196
Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, d Richon VM . (2000). Cancer Res. 60: 5165–5170
Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR . Blood 1999 94: 1401–1408
Chambon P . 1996 FASEB J. 10: 940–954
Coffey DC, Kutko MC, Glick RD, Swendeman SL, Butler L, Rifkind R, Marks PA, Richon VM, LaQuaglia MP . 2000 Med. Pediatr. Oncol. 35: 577–581
Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D, Richon VM . 1999 Anticancer Res. 19: 4999–5005
Dervan PB, Burli RW . 1999 Curr. Opin. Chem. Biol. 3: 688–693
Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, Kerckaert JP, Evans RM, Leprince D . 1997 Proc. Natl. Acad. Sci. USA 94: 10762–10767
Dover GJ, Brusilow S, Samid D . 1992 N. Engl. J. Med. 327: 569–570
Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich N . 1999 Nature 401: 188–193
Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA . 1998 Mol. Cell. Biol. 18: 7185–7191
Gottesfeld JM, Neely L, Trauger JW, Baird EE, Dervan PB . 1997 Nature 387: 202–205
Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Lazar MA, Minucci S, Pelicci PG . 1998 Nature 391: 815–818
Grunstein M . 1997 Nature 389: 349–352
Gudas L, Sporn M, Roberts A . 1994 Raven Press, New York pp. 443–520
He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP . 1998a Nat. Genet. 18: 126–135
He LZ, Tolentino T, Warrell Jr. RP, Zelent A, Rifkind RA, Marks PA, Richon VM, Pandolfi PP . 1998b Blood 92: Suppl 1 510a
He LZ, Merghoub T, Pandolfi PP . 1999 Oncogene 18: 5278–5292
He L, Bhaumik M, Tribioli C, Rego EM, Ivins S, Zelent A, Pandolfi PP . 2000 Mol. Cell 6: 1131–1141
Huang L, Sowa Y, Sakai T, Pardee AB . 2000 Oncogene 19: 5712–5719
Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, Pehamberger H . 2000 Lancet 18: 1728–1733
Janssen S, Durussel T, Laemmli UK . 2000 Mol. Cell 6: 999–1011
Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA . 2000 Clin. Cancer Res. 6: 372–380
Koken MH, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A, Minard P, Degos L, Varet B, de The H . 1999 Oncogene 18: 1113–1118
Kushner DM, Silverman RH . 2000 Curr. Oncol. Rep. 2: 23–30
Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, Haber DA . (999 Cell 98: 663–673
Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller Jr WH, Zelenetz AD, Willman CL, Chen Z, Chen S-J, Zelent A, Macintyre E, Veil A, Cortes J, Kantarjian H, Waxman S . 1995 Blood 85: 1083–1094
Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr. WH, Evans RM . 1998 Nature 391: 811–814
Lin RJ, Evans RM . 2000 Mol. Cell. 5: 821–830
Liu PQ, Rebar EJ, Zhang L, Liu Q, Jamieson AC, Liang Y, Qi H, Li PX, Chen B, Mendel MC, Zhong X, Lee YL, Eisenberg S, Spratt SK, Case CC, Wolffe AP . 2001 J. Biol. Chem. in press.
Lo Coco F, Ye BH, Lista F, Corradini P, Offit K, Knowles DM, Chaganti RSK, Dalla-Favera R . 1994 Blood 83: 1757–1759
Look AT . 1997 Science 278: 1059–1064
Maeda T, Towatari M, Kosugi H, Saito H . 2000 Blood 96: 3847–3856
Magrath I . 1990 In The Non-Hodgkin's Lymphoma., Magrath, I. (ed) Williams and Wilkins, Baltimore pp. 29–48
Mapp AK, Ansari AZ, Ptashne M, Dervan PB . 2000 Proc. Natl. Acad. Sci. USA 97: 3930–3935
Marks PA, Richon VM, Rifkind RA . 2000 J. Natl. Cancer Inst. 92: 1210–1216
Melnick A, Licht JD . 1999 Blood 93: 3167–3215
Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S, Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E, Schiavoni I, Badaracco G, Hu X, Lazar MA, Landsberger N, Nervi C, Pelicci PG . 2000 Mol. Cell. 5: 811–820
Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A . 1998 Nature 393: 386–389
Rego EM, He LZ, Warrell Jr. RP, Wang ZG, Pandolfi PP . 2000 Proc. Natl. Acad. Sci. USA 97: 10173–10178
Reich S, Buhrer C, Henze G, Ohlendorf D, Mesche M, Sinha P, Kage A, Muller C, Vetter B, Kulozik AE . 2000 Blood 96: 3357–3363
Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA . 1996 Proc. Natl. Acad. Sci. USA 93: 5705–5708
Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA . 1998 Proc. Natl. Acad. Sci. USA 95: 3003–3007
Richon VM, Sandhoff TW, Rifkind RA, Marks PA . 2000 Proc. Natl. Acad. Sci. USA 97: 10014–10019
Ruiz i Altaba A . 1999 Trends Genet. 15: 418–425
Salomoni P, Pandolfi PP . 2000 Nat. Med. 6: 742–744
Schwaller J, Parganas E, Wang D, Cain D, Aster JC, Williams IR, Lee CK, Gerthner R, Kitamura T, Frantsve J, Anastasiadou E, Loh ML, Levy DE, Ihle JN, Gilliland DG . 2000 Mol. Cell. 6: 693–704
Smith MA, Parkinson DR, Cheson BD, Friedman MA . 1999 J. Clin. Oncol. 10: 839–864
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell Jr. RP . 1998 N. Engl. J. Med. 339: 1341–1348
Trauger J, Baird E, Dervan PB . 1998 J. Am. Chem. Soc. 120: 3534–3535
Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, Grant S . 1999 Oncogene. 18: 7016–7025
Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM . 1998 Proc. Natl. Acad. Sci. USA 95: 10860–10865
Warrell Jr. RP, He LZ, Richon V, Calleja E, Pandolfi PP . 1998 J. Natl. Cancer Inst. 90: 1621–1625
White S, Szewczyk JW, Turner JM, Baird EE, Dervan PB . 1998 Nature 391: 468–471
Wolffe AP . 2001 Oncogene in press.
Ye BH, Chaganti S, Chang CC, Niu H, Corradini P, Chaganti RSK, Dalla Favera R . 1995 EMBO J. 14: 6209–6217
Zhang L, Spratt SK, Liu Q, Johnstone B, Qi H, Raschke EE, Jamieson AC, Rebar EJ, Wolffe AP, Case CC . 2000 J. Biol. Chem. 27: 33850–33860
Acknowledgements
We would like to thank Aseem Ansari for critical suggestions, as well as Victoria Richon, Ray Warrell and members of the laboratory of Molecular and Developmental Biology (MADB) laboratory at Memorial Sloan-Kettering Cancer Center for useful discussions. PP Pandolfi is a Scholar of the Lymphoma Leukemia Society. This work is supported by the NCI, the De Witt Wallace Fund for Memorial Sloan-Kettering Cancer Center, the MMHCC and NIH Grants to PP Pandolfi.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pandolfi, P. Transcription therapy for cancer. Oncogene 20, 3116–3127 (2001). https://doi.org/10.1038/sj.onc.1204299
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204299
Keywords
This article is cited by
-
Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies
Indian Journal of Surgical Oncology (2021)
-
Effects of endostatin and a new drug terpestacin against human neuroblastoma xenograft and cell lines
Pediatric Surgery International (2013)
-
Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition
Cancer Cell International (2012)
-
DNA minor groove binding of small molecules: Experimental and computational evidence
Journal of Chemical Sciences (2010)
-
A New Microsphere-Based Immunoassay for Measuring the Activity of Transcription Factors
Biological Procedures Online (2010)